- Coronavirus disease 2019 (COVID-19) vaccine platforms: how novel platforms can prepare us for future pandemics: a narrative review
-
Jae Kyung Lee, Ok Sarah Shin
-
J Yeungnam Med Sci. 2022;39(2):89-97. Published online February 14, 2022
-
DOI: https://doi.org/10.12701/jyms.2021.01669
-
-
3,153
View
-
73
Download
-
1
Web of Science
-
1
Crossref
-
 Abstract
 PDF
- More than 2 years after the explosion of the coronavirus disease 2019 (COVID-19) pandemic, extensive efforts have been made to develop safe and efficacious vaccines against infections with severe acute respiratory syndrome coronavirus 2. The pandemic has opened a new era of vaccine development based on next-generation platforms, including messenger RNA (mRNA)-based technologies, and paved the way for the future of mRNA-based therapeutics to provide protection against a wide range of infectious diseases. Multiple vaccines have been developed at an unprecedented pace to protect against COVID-19 worldwide. However, important knowledge gaps remain to be addressed, especially in terms of how vaccines induce immunogenicity and efficacy in those who are elderly. Here, we discuss the various vaccine platforms that have been utilized to combat COVID-19 and emphasize how these platforms can be a powerful tool to react quickly to future pandemics.
-
Citations
Citations to this article as recorded by  - Preclinical evaluation of immunogenicity, efficacy and safety of a recombinant plant-based SARS-CoV-2 RBD vaccine formulated with 3M-052-Alum adjuvant
Waranyoo Phoolcharoen, Balamurugan Shanmugaraj, Narach Khorattanakulchai, Piyanate Sunyakumthorn, Sathit Pichyangkul, Pornnarin Taepavarapruk, Wanlapa Praserthsee, Suchinda Malaivijitnond, Suwimon Manopwisedjaroen, Arunee Thitithanyanont, Kanjana Srisutth
Vaccine.2023; 41(17): 2781. CrossRef
|
E-Submission
Yeungnam University College of Medicine
